Karyopharm Shares Plunge After Selinexor Misses in Endometrial Cancer Trial
Karyopharm seeks accelerated FDA approval for selinexor combined with ruxolitinib—the potential first novel combo therapy for myelofibrosis patients.
/ 4 items
#KPTI↓
Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.
Half the Patients Saw Dramatic Spleen Shrinkage: SENTRY Trial Shows Strong Results (With One Notable Miss) for New Myelofibrosis Combo
Karyopharm’s (KPTI) SENTRY trial delivers strong spleen reduction and promising survival data with selinexor + ruxolitinib — though symptom improvement was not superior. $30M cash boost extends runway into late 2026.
H.C. Wainwright Upgrades Karyopharm to Buy on Strategic Financing
H.C. Wainwright upgrades Karyopharm to Buy with $15 price target following strategic financing that extends cash runway beyond Phase 3 SENTRY trial results.